Durvalumab 50 MG/1 ML Intravenous Solution + Etoposide Injection + Cisplatin + Carboplatin
Phase 1Active 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small-cell Lung Cancer
Conditions
Extensive-stage Small-cell Lung Cancer
Trial Timeline
Jun 30, 2026 → Aug 1, 2027
NCT ID
NCT05403723About Durvalumab 50 MG/1 ML Intravenous Solution + Etoposide Injection + Cisplatin + Carboplatin
Durvalumab 50 MG/1 ML Intravenous Solution + Etoposide Injection + Cisplatin + Carboplatin is a phase 1 stage product being developed by AstraZeneca for Extensive-stage Small-cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05403723. Target conditions include Extensive-stage Small-cell Lung Cancer.
What happened to similar drugs?
0 of 7 similar drugs in Extensive-stage Small-cell Lung Cancer were approved
Approved (0) Terminated (1) Active (6)
🔄Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
🔄BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + EtoposideBristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05403723 | Phase 1 | Active |
Competing Products
20 competing products in Extensive-stage Small-cell Lung Cancer